Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cigna GroupCI · Entity 550 | See Remarks | September 03, 2026 | September 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cigna Group
Report date September 03, 2026 · Filed September 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $.01 Par ValueSEC Table I · non-derivative | Direct | 5,053 |
Reported balance
After 2026-09-03 transaction · row 1
1 source rowRow 1 · 2026-09-03 · Sale · Disposed 617 · Balance 5,053 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 2, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 2, 2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Express Scripts Holding Co.
Report date December 20, 2018 · Filed December 21, 2018
Section 16 reporting ended · disclosed 2018-12-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 1
1 source rowRow 1 · 2018-12-20 · Disposition to issuer · Disposed 31,049 · Balance 0 F1: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Cigna Corporation, Halfmoon Parent, Inc., Halfmoon I, Inc. and Halfmoon II, Inc., upon closing of the merger of Halfmoon II, Inc. with and into the Issuer (the "Merger"), each common share of the Issuer was converted into the right to receive 0.2434 shares of Halfmoon Parent, Inc. common stock and $48.75 in cash. Each restricted stock unit was converted into a unit with respect to common stock of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $58.17 · Expires 2020-03-06 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-12-20 · Disposition to issuer · Disposed 2,237 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $77.15 · Expires 2021-03-05 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-12-20 · Disposition to issuer · Disposed 9,387 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $84.83 · Expires 2025-03-04 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-12-20 · Disposition to issuer · Disposed 9,121 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $84.08 · Expires 2025-05-06 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-12-20 · Disposition to issuer · Disposed 16,272 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $69.57 · Expires 2026-03-09 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-12-20 · Disposition to issuer · Disposed 42,643 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $67.62 · Expires 2027-03-08 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-12-20 · Disposition to issuer · Disposed 51,980 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. |
| Phantom Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2018-12-20 · Disposition to issuer · Disposed 951.6605 · Balance 0 F4: Phantom Stock Unit credited under the Company's Executive Deferred Compensation Plan. F5: Upon distribution, each phantom stock unit would have converted into one share of the Issuer's common stock. F6: Pursuant to the Merger Agreement, upon closing of the Merger, each phantom stock unit was converted into a stock unit relating to the common stock of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F7: Basic Company Credit by the Issuer to Reporting Person's Account in the Executive Deferred Compensation Plan; shares vest 3 (three) years after the plan year to which such credit relates. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Cigna Corporation, Halfmoon Parent, Inc., Halfmoon I, Inc. and Halfmoon II, Inc., upon closing of the merger of Halfmoon II, Inc. with and into the Issuer (the "Merger"), each common share of the Issuer was converted into the right to receive 0.2434 shares of Halfmoon Parent, Inc. common stock and $48.75 in cash. Each restricted stock unit was converted into a unit with respect to common stock of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement.
F2: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted.
F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement.
F4: Phantom Stock Unit credited under the Company's Executive Deferred Compensation Plan.
F5: Upon distribution, each phantom stock unit would have converted into one share of the Issuer's common stock.
F6: Pursuant to the Merger Agreement, upon closing of the Merger, each phantom stock unit was converted into a stock unit relating to the common stock of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement.
F7: Basic Company Credit by the Issuer to Reporting Person's Account in the Executive Deferred Compensation Plan; shares vest 3 (three) years after the plan year to which such credit relates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 03, 2022 Filed Jan 5, 2022 22:32 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 4,800 | $229.49 | $1,101,552.00 |
DisclosureSEC source: 0001225208-22-000493 · doc4.xml · nonDerivative · entry 1 Neville Everett · CIK 0001641142 · EVP, Strategy and Business Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,781 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 4, 2021. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 21:47 UTC | Cigna Group CI · Entity 550 | OtherPhantom Stock Units · Derivative | 10,568.6172 | $238.30 Strike: $0.00 | $2,518,501.48 |
DisclosureSEC source: 0001225208-21-010315 · doc4.xml · derivative · entry 1 Neville Everett · CIK 0001641142 · EVP, Strategy and Business Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,990.8431 Underlying: Common Stock, $.01 Par Value · 10,568.6172 shares Expires not disclosed F1 · derivative.exercise_price: Represents phantom stock units under the Cigna stock fund of the Express Scripts, Inc. Executive Deferred Compensation Plan. Each phantom stock unit represents the right to receive the cash value of one share of Cigna stock. F2 · date: Reporting person provided the instruction to invest in the Cigna stock fund on June 3, 2021. F3 · derivative.exercise_date: Phantom stock units are payable in cash in accordance with the terms of the Express Scripts, Inc. Executive Deferred Compensation Plan. The reporting person may transfer his interests in the Cigna stock fund into an alternative investment account. F3 · derivative.expiration_date: Phantom stock units are payable in cash in accordance with the terms of the Express Scripts, Inc. Executive Deferred Compensation Plan. The reporting person may transfer his interests in the Cigna stock fund into an alternative investment account. F4 · balance_after: Includes 3.5394 phantom stock units acquired pursuant to a dividend reinvestment feature of the Express Scripts, Inc. Executive Deferred Compensation Plan. Read SEC document |
| February 26, 2021 Filed Mar 3, 2021 01:27 UTC | Cigna Group CI · Entity 550 | Tax withholdingCommon Stock, $.01 Par Value | 407 | $210.31 | $85,596.17 |
DisclosureSEC source: 0001225208-21-004357 · doc4.xml · nonDerivative · entry 3 Neville Everett · CIK 0001641142 · EVP, Strategy and Business Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,581 F3 · shares: Represents shares withheld to satisfy tax obligations upon settlement of strategic performance shares. Read SEC document |
| February 26, 2021 Filed Mar 3, 2021 01:27 UTC | Cigna Group CI · Entity 550 | Tax withholdingCommon Stock, $.01 Par Value | 226 | $210.31 | $47,530.06 |
DisclosureSEC source: 0001225208-21-004357 · doc4.xml · nonDerivative · entry 2 Neville Everett · CIK 0001641142 · EVP, Strategy and Business Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,988 F2 · shares: Represents shares withheld to satisfy tax obligations upon vesting of restricted shares. Read SEC document |
| February 26, 2021 Filed Mar 3, 2021 01:27 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 1,387 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-004357 · doc4.xml · nonDerivative · entry 1 Neville Everett · CIK 0001641142 · EVP, Strategy and Business Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,214 F1 · shares: The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2018-2020 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals. Read SEC document |
| February 24, 2021 Filed Feb 27, 2021 01:23 UTC | Cigna Group CI · Entity 550 | GrantEmployee Stock Option (Right to Buy) · Derivative | 11,710 | $0.00 Strike: $213.80 | $0.00 |
DisclosureSEC source: 0001225208-21-003980 · doc4.xml · derivative · entry 2 Neville Everett · CIK 0001641142 · EVP, Strategy and Business Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,710 Underlying: Common Stock, $.01 Par Value · 11,710 shares Expires 2031-02-24 F2 · derivative.exercise_date: This option vests in three equal annual installments beginning March 1, 2022. Read SEC document |
| February 24, 2021 Filed Feb 27, 2021 01:23 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 2,456 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003980 · doc4.xml · nonDerivative · entry 1 Neville Everett · CIK 0001641142 · EVP, Strategy and Business Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,827 F1 · shares: These restricted shares vest in three equal annual installments beginning March 1, 2022. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 17:06 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Disposition to issuerPhantom Stock Units · Derivative | 951.6605 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000950138-18-000695 · edgar.xml · derivative · entry 8 Neville Everett · CIK 0001641142 · Exe VP, Strat, Sup Chn & Spclt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Express Scripts Holding Company Common Stock · 951.6605 shares Expires not disclosed F4 · security: Phantom Stock Unit credited under the Company's Executive Deferred Compensation Plan. F5 · derivative.exercise_price: Upon distribution, each phantom stock unit would have converted into one share of the Issuer's common stock. F6 · kind: Pursuant to the Merger Agreement, upon closing of the Merger, each phantom stock unit was converted into a stock unit relating to the common stock of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F5 · price: Upon distribution, each phantom stock unit would have converted into one share of the Issuer's common stock. F7 · derivative.exercise_date: Basic Company Credit by the Issuer to Reporting Person's Account in the Executive Deferred Compensation Plan; shares vest 3 (three) years after the plan year to which such credit relates. F7 · derivative.expiration_date: Basic Company Credit by the Issuer to Reporting Person's Account in the Executive Deferred Compensation Plan; shares vest 3 (three) years after the plan year to which such credit relates. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 17:06 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Disposition to issuerNon-Qualified Stock Option (Right to Buy) · Derivative | 51,980 | $0.00 Strike: $67.62 | $0.00 |
DisclosureSEC source: 0000950138-18-000695 · edgar.xml · derivative · entry 7 Neville Everett · CIK 0001641142 · Exe VP, Strat, Sup Chn & Spclt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Express Scripts Holding Company Common Stock · 51,980 shares Expires 2027-03-08 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 17:06 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Disposition to issuerNon-Qualified Stock Option (Right to Buy) · Derivative | 42,643 | $0.00 Strike: $69.57 | $0.00 |
DisclosureSEC source: 0000950138-18-000695 · edgar.xml · derivative · entry 6 Neville Everett · CIK 0001641142 · Exe VP, Strat, Sup Chn & Spclt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Express Scripts Holding Company Common Stock · 42,643 shares Expires 2026-03-09 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 17:06 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Disposition to issuerNon-Qualified Stock Option (Right to Buy) · Derivative | 16,272 | $0.00 Strike: $84.08 | $0.00 |
DisclosureSEC source: 0000950138-18-000695 · edgar.xml · derivative · entry 5 Neville Everett · CIK 0001641142 · Exe VP, Strat, Sup Chn & Spclt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Express Scripts Holding Company Common Stock · 16,272 shares Expires 2025-05-06 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 17:06 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Disposition to issuerNon-Qualified Stock Option (Right to Buy) · Derivative | 9,121 | $0.00 Strike: $84.83 | $0.00 |
DisclosureSEC source: 0000950138-18-000695 · edgar.xml · derivative · entry 4 Neville Everett · CIK 0001641142 · Exe VP, Strat, Sup Chn & Spclt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Express Scripts Holding Company Common Stock · 9,121 shares Expires 2025-03-04 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 17:06 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Disposition to issuerNon-Qualified Stock Option (Right to Buy) · Derivative | 9,387 | $0.00 Strike: $77.15 | $0.00 |
DisclosureSEC source: 0000950138-18-000695 · edgar.xml · derivative · entry 3 Neville Everett · CIK 0001641142 · Exe VP, Strat, Sup Chn & Spclt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Express Scripts Holding Company Common Stock · 9,387 shares Expires 2021-03-05 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 17:06 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Disposition to issuerNon-Qualified Stock Option (Right to Buy) · Derivative | 2,237 | $0.00 Strike: $58.17 | $0.00 |
DisclosureSEC source: 0000950138-18-000695 · edgar.xml · derivative · entry 2 Neville Everett · CIK 0001641142 · Exe VP, Strat, Sup Chn & Spclt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Express Scripts Holding Company Common Stock · 2,237 shares Expires 2020-03-06 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 17:06 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Disposition to issuerCommon Stock | 31,049 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-18-000695 · edgar.xml · nonDerivative · entry 1 Neville Everett · CIK 0001641142 · Exe VP, Strat, Sup Chn & Spclt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Cigna Corporation, Halfmoon Parent, Inc., Halfmoon I, Inc. and Halfmoon II, Inc., upon closing of the merger of Halfmoon II, Inc. with and into the Issuer (the "Merger"), each common share of the Issuer was converted into the right to receive 0.2434 shares of Halfmoon Parent, Inc. common stock and $48.75 in cash. Each restricted stock unit was converted into a unit with respect to common stock of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:42 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Tax withholdingCommon Stock | 522 | $70.22 | $36,654.84 |
DisclosureSEC source: 0000950138-18-000352 · edgar.xml · nonDerivative · entry 1 Neville Everett · CIK 0001641142 · Exe VP, Strat, Sup Chn & Spclt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,049 F1 · shares: Represents shares tendered to Company to cover Reporting Person's tax liability due upon vesting of restricted stock units previously awarded under long-term incentive plans. Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 18:49 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Tax withholdingCommon Stock | 1,310 | $74.58 | $97,699.80 |
DisclosureSEC source: 0000950138-18-000252 · edgar.xml · nonDerivative · entry 3 Neville Everett · CIK 0001641142 · Exe VP, Strat, Sup Chn & Spclt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,571 F3 · shares: Represents shares tendered to Company to cover Reporting Person's tax liability due upon vesting of performance shares. Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 18:49 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | GrantCommon Stock | 4,316 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-18-000252 · edgar.xml · nonDerivative · entry 2 Neville Everett · CIK 0001641142 · Exe VP, Strat, Sup Chn & Spclt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,881 F2 · price: Vesting of performance shares granted under Express Scripts, Inc. 2011 Long-Term Incentive Plan. Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 18:49 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | GrantCommon Stock | 17,389 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-18-000252 · edgar.xml · nonDerivative · entry 1 Neville Everett · CIK 0001641142 · Exe VP, Strat, Sup Chn & Spclt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,565 F1 · price: Grant of restricted stock units pursuant to Express Scripts Holding Company 2016 Long-Term Incentive Plan. Awards vest in three equal installments on February 28, 2019, February 28, 2020, and February 28, 2021. Read SEC document |
| March 01, 2018 Filed Mar 2, 2018 16:40 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | SaleCommon Stock | 4,895 | $75.26 | $368,397.70 |
DisclosureSEC source: 0000950138-18-000198 · edgar.xml · nonDerivative · entry 2 Neville Everett · CIK 0001641142 · Exe VP, Strat, Sup Chn & Spclt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,176 F2 · shares: The sale transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 16:40 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Tax withholdingCommon Stock | 2,161 | $75.45 | $163,047.45 |
DisclosureSEC source: 0000950138-18-000198 · edgar.xml · nonDerivative · entry 1 Neville Everett · CIK 0001641142 · Exe VP, Strat, Sup Chn & Spclt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,071 F1 · shares: Represents shares tendered to Company to cover Reporting Person's tax liability due upon vesting of restricted stock units previously awarded under long-term incentive plans. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 16:30 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | GrantPhantom Stock Unit · Derivative | 185.0332 | $78.10 Strike: $0.00 | $14,451.09 |
DisclosureSEC source: 0000950138-18-000097 · edgar.xml · derivative · entry 1 Neville Everett · CIK 0001641142 · Exe VP, Strat, Sup Chn & Spclt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 890.4424 Underlying: Express Scripts Holding Company Common Stock · 185.0332 shares Expires not disclosed F1 · security: Phantom Stock Unit credited under the Company's Executive Deferred Compensation Plan. F2 · derivative.exercise_price: Upon distribution each Phantom Stock Unit converts to one share of the Company's Common Stock. F3 · derivative.exercise_date: Basic Company Credit by Express Scripts Holding Company to Participant's Account in the Executive Deferred Compensation Plan; shares vest 3 (three) years after the plan year to which such credit relates. F3 · derivative.expiration_date: Basic Company Credit by Express Scripts Holding Company to Participant's Account in the Executive Deferred Compensation Plan; shares vest 3 (three) years after the plan year to which such credit relates. Read SEC document |
| August 23, 2017 Filed Aug 25, 2017 16:05 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | SaleCommon Stock | 1,163 | $61.48 | $71,501.24 |
DisclosureSEC source: 0000950138-17-000604 · edgar.xml · nonDerivative · entry 1 Neville Everett · CIK 0001641142 · Sr. VP, Sup. Chain & Specialty 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,232 F1 · shares: The sale transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| May 06, 2017 Filed May 9, 2017 16:10 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Tax withholdingCommon Stock | 384 | $61.58 | $23,646.72 |
DisclosureSEC source: 0000950138-17-000381 · edgar.xml · nonDerivative · entry 1 Neville Everett · CIK 0001641142 · Sr VP-Supply Chain & Specialty 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,395 F1 · shares: Represents shares tendered to Company to cover Reporting Person's tax liability due upon vesting of restricted stock units previously awarded under long-term incentive plans. Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 16:07 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | GrantNon-Qualified Stock Option (Right-to-Buy) · Derivative | 51,980 | Not disclosed Strike: $67.62 | Not disclosed |
DisclosureSEC source: 0000950138-17-000310 · edgar.xml · derivative · entry 2 Neville Everett · CIK 0001641142 · Sr VP-Supply Chain & Specialty 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,980 Underlying: Express Scripts Holding Company Common Stock · 51,980 shares Expires 2027-03-08 F2 · price: Grant of stock option pursuant to Express Scripts Holding Company 2016 Long-Term Incentive Plan. Vests in three equal installments on February 28, 2018, February 28, 2019, and February 28, 2020. F2 · derivative.exercise_date: Grant of stock option pursuant to Express Scripts Holding Company 2016 Long-Term Incentive Plan. Vests in three equal installments on February 28, 2018, February 28, 2019, and February 28, 2020. Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 16:07 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | GrantCommon Stock | 10,844 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-17-000310 · edgar.xml · nonDerivative · entry 1 Neville Everett · CIK 0001641142 · Sr VP-Supply Chain & Specialty 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,779 F1 · price: Grant of restricted stock units pursuant to Express Scripts Holding Company 2016 Long-Term Incentive Plan. Awards vest in three equal installments on February 28, 2018, February 28, 2019, and February 28, 2020. Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 16:29 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | SaleCommon Stock | 2,352 | $70.16 | $165,016.32 |
DisclosureSEC source: 0000950138-17-000226 · edgar.xml · nonDerivative · entry 2 Neville Everett · CIK 0001641142 · Sr VP-Supply Chain & Specialty 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,935 F2 · shares: The sale transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 16:29 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Tax withholdingCommon Stock | 1,425 | $70.65 | $100,676.25 |
DisclosureSEC source: 0000950138-17-000226 · edgar.xml · nonDerivative · entry 1 Neville Everett · CIK 0001641142 · Sr VP-Supply Chain & Specialty 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,287 F1 · shares: Represents shares tendered to Company to cover Reporting Person's tax liability due upon vesting of restricted stock units previously awarded under long-term incentive plan. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 16:05 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | GrantPhantom Stock Unit · Derivative | 198.703 | $69.11 Strike: $0.00 | $13,732.36 |
DisclosureSEC source: 0000950138-17-000101 · edgar.xml · derivative · entry 1 Neville Everett · CIK 0001641142 · Sr VP-Supply Chain & Specialty 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 705.4092 Underlying: Express Scripts Holding Company Common Stock · 198.703 shares Expires not disclosed F1 · security: . Phantom Stock Unit credited under the Company's Executive Deferred Compensation Plan. F2 · derivative.exercise_price: Upon distribution each Phantom Stock Unit converts to one share of the Company's Common Stock. F3 · derivative.exercise_date: Basic Company Credit by Express Scripts Holding Company to Participant's Account in the Executive Deferred Compensation Plan; shares vest 3 (three) years after the plan year to which such credit relates F3 · derivative.expiration_date: Basic Company Credit by Express Scripts Holding Company to Participant's Account in the Executive Deferred Compensation Plan; shares vest 3 (three) years after the plan year to which such credit relates Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 16:01 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | SaleCommon Stock | 1,123 | $69.41 | $77,947.43 |
DisclosureSEC source: 0000950138-17-000030 · edgar.xml · nonDerivative · entry 1 Neville Everett · CIK 0001641142 · Sr. VP, Sup. Chain & Specialty 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,712 F1 · shares: The sale transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 04, 2016 Filed Mar 15, 2017 16:02 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | OtherPhantom Stock Units · Derivative | 36.034 | $86.63 Strike: $0.00 | $3,121.63 |
DisclosureSEC source: 0000950138-17-000321 · edgar.xml · derivative · entry 2 Neville Everett · CIK 0001641142 · Sr VP-Supply Chain & Specialty 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 766.6272 Underlying: Express Scripts Holding Company Common Stock · 36.034 shares Expires not disclosed F1 · security: Phantom Stock Units acquired under the Company's Executive Deferred Compensation Plan. These transactions were not timely reported due to internal administrative error. F2 · derivative.exercise_price: Upon distribution each Phantom Stock Unit converts to one share of the Company's Common Stock. Phantom Stock Units reflected herein may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.exercise_date: Upon distribution each Phantom Stock Unit converts to one share of the Company's Common Stock. Phantom Stock Units reflected herein may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: Upon distribution each Phantom Stock Unit converts to one share of the Company's Common Stock. Phantom Stock Units reflected herein may be transferred by the reporting person into an alternative investment account at any time. F3 · balance_after: Total reflects contributions of Phantom Stock Units subsequent to the two transactions reported on this Form 4. Read SEC document |
| October 07, 2015 Filed Mar 15, 2017 16:02 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | OtherPhantom Stock Units · Derivative | 25.184 | $82.57 Strike: $0.00 | $2,079.44 |
DisclosureSEC source: 0000950138-17-000321 · edgar.xml · derivative · entry 1 Neville Everett · CIK 0001641142 · Sr VP-Supply Chain & Specialty 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 730.5932 Underlying: Express Scripts Holding Company Common Stock · 25.184 shares Expires not disclosed F1 · security: Phantom Stock Units acquired under the Company's Executive Deferred Compensation Plan. These transactions were not timely reported due to internal administrative error. F2 · derivative.exercise_price: Upon distribution each Phantom Stock Unit converts to one share of the Company's Common Stock. Phantom Stock Units reflected herein may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.exercise_date: Upon distribution each Phantom Stock Unit converts to one share of the Company's Common Stock. Phantom Stock Units reflected herein may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: Upon distribution each Phantom Stock Unit converts to one share of the Company's Common Stock. Phantom Stock Units reflected herein may be transferred by the reporting person into an alternative investment account at any time. F3 · balance_after: Total reflects contributions of Phantom Stock Units subsequent to the two transactions reported on this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.